Enliven Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard A. Fair
- Full Time Employees
- 61
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6200 Lookout Road Boulder CO United States of America 80301
- IPO Date
- Mar 12, 2020
- CIK
- 0001672619
- Website
- enliventherapeutics.com
- Similar Companies
- Business
- Enliven Therapeutics, Inc. (Nasdaq: ELVN) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule kinase inhibitors for the treatment of cancer patients. The company's lead product candidate, ELVN-001, is a potent, highly selective BCR-ABL kinase inhibitor in Phase 1 clinical development (ENABLE-1 trial, NCT05304377) for chronic myeloid leukemia (CML) across multiple lines of therapy, including patients with the T315I resistance mutation; ELVN-002 is a CNS-penetrant, irreversible HER2 inhibitor in Phase 1 trials (NCT05650879 and NCT06328738) for HER2-expressing or mutated solid tumors including non-small cell lung cancer, breast cancer and colorectal cancer, both as monotherapy and in combinations with trastuzumab, ado-trastuzumab emtansine and trastuzumab deruxtecan; the company is advancing earlier-stage programs including a Type 1 pan-RAF inhibitor (ELV-3111). Enliven Therapeutics, founded in 2019, is headquartered in Boulder, Colorado. Recent developments include positive Phase 1 data for ELVN-001 demonstrating a 44% major molecular response rate by 12 weeks in heavily pretreated CML patients, completion of randomized Phase 1b enrollment in the ENABLE trial and readiness for a global Phase 3 pivotal trial initiation in 2026; expansion of the ELVN-002 program with ongoing combination dosing and planned data readouts; a $230 million public offering in June 2025 that extended cash runway into mid-2029 alongside prior $200 million and $90 million raises; FDA orphan drug designation for ELVN-001; and multiple data presentations at 2025 conferences including EHA, SOHO and AACR. The company targets precision oncology indications with unmet needs in tolerability, resistance and brain metastases, operating primarily in the United States with global clinical trial sites.
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
Enliven Therapeutics to Present at Upcoming Investor Conferences
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why